|
|
| Line 4: |
Line 4: |
|
| |
|
| ==Overview== | | ==Overview== |
| There is no treatment for [disease name]; the mainstay of therapy is supportive care.
| | Surgical intervention is not recommended for the management of [disease name]. |
|
| |
|
| OR | | OR |
|
| |
|
| Supportive therapy for [disease name] includes [therapy 1], [therapy 2], and [therapy 3].
| | Surgery is not the first-line treatment option for patients with [disease name]. Surgery is usually reserved for patients with either [indication 1], [indication 2], and [indication 3] |
|
| |
|
| OR | | OR |
|
| |
|
| The majority of cases of [disease name] are self-limited and require only supportive care. | | The mainstay of treatment for [disease name] is medical therapy. Surgery is usually reserved for patients with either [indication 1], [indication 2], and/or [indication 3]. |
|
| |
|
| OR | | OR |
|
| |
|
| [Disease name] is a medical emergency and requires prompt treatment. | | The feasibility of surgery depends on the stage of [malignancy] at diagnosis. |
|
| |
|
| OR | | OR |
|
| |
|
| The mainstay of treatment for [disease name] is [therapy].
| | Surgery is the mainstay of treatment for [disease or malignancy]. |
|
| |
|
| | == Indication == |
| | * Surgical intervention is not recommended for the management of [disease name]. |
| OR | | OR |
|
| | * Surgery is not the first-line treatment option for patients with [disease name]. Surgery is usually reserved for patients with either: |
| The optimal therapy for [malignancy name] depends on the stage at diagnosis. | | ** [Indication 1] |
| | ** [Indication 2] |
| | ** [Indication 3] |
| | * The mainstay of treatment for [disease name] is medical therapy. Surgery is usually reserved for patients with either: |
| | ** [Indication 1] |
| | ** [Indication 2] |
| | ** [Indication 3] |
|
| |
|
| OR
| | ==Surgery== |
| | | Surgical intervention may be required in some patients who have gastrointestinal complications with severe colitis that progress to necrosis and in some cases lead to intestinal perforation. |
| [Therapy] is recommended among all patients who develop [disease name].
| | ** |
| | |
| OR
| |
| | |
| Pharmacologic medical therapy is recommended among patients with [disease subclass 1], [disease subclass 2], and [disease subclass 3].
| |
| | |
| OR
| |
| | |
| Pharmacologic medical therapies for [disease name] include (either) [therapy 1], [therapy 2], and/or [therapy 3].
| |
| | |
| OR
| |
| | |
| Empiric therapy for [disease name] depends on [disease factor 1] and [disease factor 2].
| |
| | |
| OR
| |
| | |
| Patients with [disease subclass 1] are treated with [therapy 1], whereas patients with [disease subclass 2] are treated with [therapy 2].
| |
| | |
| ==Medical Therapy== | |
| *Pharmacologic medical therapy is recommended among patients with [disease subclass 1], [disease subclass 2], and [disease subclass 3].
| |
| *Pharmacologic medical therapies for [disease name] include (either) [therapy 1], [therapy 2], and/or [therapy 3].
| |
| *Empiric therapy for [disease name] depends on [disease factor 1] and [disease factor 2].
| |
| *Patients with [disease subclass 1] are treated with [therapy 1], whereas patients with [disease subclass 2] are treated with [therapy 2].
| |
| ===Disease Name===
| |
| | |
| * '''1 Stage 1 - Name of stage'''
| |
| ** 1.1 '''Specific Organ system involved 1'''
| |
| *** 1.1.1 '''Adult'''
| |
| **** Preferred regimen (1): [[drug name]] 100 mg PO q12h for 10-21 days '''(Contraindications/specific instructions)'''
| |
| **** Preferred regimen (2): [[drug name]] 500 mg PO q8h for 14-21 days
| |
| **** Preferred regimen (3): [[drug name]] 500 mg q12h for 14-21 days
| |
| **** Alternative regimen (1): [[drug name]] 500 mg PO q6h for 7–10 days
| |
| **** Alternative regimen (2): [[drug name]] 500 mg PO q12h for 14–21 days
| |
| **** Alternative regimen (3): [[drug name]] 500 mg PO q6h for 14–21 days
| |
| *** 1.1.2 '''Pediatric'''
| |
| **** 1.1.2.1 (Specific population e.g. '''children < 8 years of age''')
| |
| ***** Preferred regimen (1): [[drug name]] 50 mg/kg PO per day q8h (maximum, 500 mg per dose)
| |
| ***** Preferred regimen (2): [[drug name]] 30 mg/kg PO per day in 2 divided doses (maximum, 500 mg per dose)
| |
| ***** Alternative regimen (1): [[drug name]]10 mg/kg PO q6h (maximum, 500 mg per day)
| |
| ***** Alternative regimen (2): [[drug name]] 7.5 mg/kg PO q12h (maximum, 500 mg per dose)
| |
| ***** Alternative regimen (3): [[drug name]] 12.5 mg/kg PO q6h (maximum, 500 mg per dose)
| |
| ****1.1.2.2 (Specific population e.g. ''''''children < 8 years of age'''''')
| |
| ***** Preferred regimen (1): [[drug name]] 4 mg/kg/day PO q12h（maximum, 100 mg per dose）
| |
| ***** Alternative regimen (1): [[drug name]] 10 mg/kg PO q6h (maximum, 500 mg per day)
| |
| ***** Alternative regimen (2): [[drug name]] 7.5 mg/kg PO q12h (maximum, 500 mg per dose)
| |
| ***** Alternative regimen (3): [[drug name]] 12.5 mg/kg PO q6h (maximum, 500 mg per dose)
| |
| ** 1.2 '''Specific Organ system involved 2'''
| |
| *** 1.2.1 '''Adult'''
| |
| **** Preferred regimen (1): [[drug name]] 500 mg PO q8h
| |
| *** 1.2.2 '''Pediatric'''
| |
| **** Preferred regimen (1): [[drug name]] 50 mg/kg/day PO q8h (maximum, 500 mg per dose)
| |
| | |
| * 2 '''Stage 2 - Name of stage'''
| |
| ** 2.1 '''Specific Organ system involved 1 '''
| |
| **: '''Note (1):'''
| |
| **: '''Note (2)''':
| |
| **: '''Note (3):'''
| |
| *** 2.1.1 '''Adult'''
| |
| **** Parenteral regimen
| |
| ***** Preferred regimen (1): [[drug name]] 2 g IV q24h for 14 (14–21) days
| |
| ***** Alternative regimen (1): [[drug name]] 2 g IV q8h for 14 (14–21) days
| |
| ***** Alternative regimen (2): [[drug name]] 18–24 MU/day IV q4h for 14 (14–21) days
| |
| **** Oral regimen
| |
| ***** Preferred regimen (1): [[drug name]] 500 mg PO q8h for 14 (14–21) days
| |
| ***** Preferred regimen (2): [[drug name]] 100 mg PO q12h for 14 (14–21) days
| |
| ***** Preferred regimen (3): [[drug name]] 500 mg PO q12h for 14 (14–21) days
| |
| ***** Alternative regimen (1): [[drug name]] 500 mg PO q6h for 7–10 days
| |
| ***** Alternative regimen (2): [[drug name]] 500 mg PO q12h for 14–21 days
| |
| ***** Alternative regimen (3):[[drug name]] 500 mg PO q6h for 14–21 days
| |
| *** 2.1.2 '''Pediatric'''
| |
| **** Parenteral regimen
| |
| ***** Preferred regimen (1): [[drug name]] 50–75 mg/kg IV q24h for 14 (14–21) days (maximum, 2 g)
| |
| ***** Alternative regimen (1): [[drug name]] 150–200 mg/kg/day IV q6–8h for 14 (14–21) days (maximum, 6 g per day)
| |
| ***** Alternative regimen (2): [[drug name]] 200,000–400,000 U/kg/day IV q4h for 14 (14–21) days (maximum, 18–24 million U per day) ''''''(Contraindications/specific instructions)''''''
| |
| **** Oral regimen
| |
| ***** Preferred regimen (1): [[drug name]] 50 mg/kg/day PO q8h for 14 (14–21) days (maximum, 500 mg per dose)
| |
| ***** Preferred regimen (2): [[drug name]] '''(for children aged ≥ 8 years)''' 4 mg/kg/day PO q12h for 14 (14–21) days (maximum, 100 mg per dose)
| |
| ***** Preferred regimen (3): [[drug name]] 30 mg/kg/day PO q12h for 14 (14–21) days (maximum, 500 mg per dose)
| |
| ***** Alternative regimen (1): [[drug name]] 10 mg/kg PO q6h 7–10 days (maximum, 500 mg per day)
| |
| ***** Alternative regimen (2): [[drug name]] 7.5 mg/kg PO q12h for 14–21 days (maximum, 500 mg per dose)
| |
| ***** Alternative regimen (3): [[drug name]] 12.5 mg/kg PO q6h for 14–21 days (maximum,500 mg per dose) | |
| ** 2.2 '<nowiki/>'''''Other Organ system involved 2''''''
| |
| **: '''Note (1):'''
| |
| **: '''Note (2)''':
| |
| **: '''Note (3):'''
| |
| *** 2.2.1 '''Adult'''
| |
| **** Parenteral regimen
| |
| ***** Preferred regimen (1): [[drug name]] 2 g IV q24h for 14 (14–21) days
| |
| ***** Alternative regimen (1): [[drug name]] 2 g IV q8h for 14 (14–21) days
| |
| ***** Alternative regimen (2): [[drug name]] 18–24 MU/day IV q4h for 14 (14–21) days
| |
| **** Oral regimen
| |
| ***** Preferred regimen (1): [[drug name]] 500 mg PO q8h for 14 (14–21) days
| |
| ***** Preferred regimen (2): [[drug name]] 100 mg PO q12h for 14 (14–21) days
| |
| ***** Preferred regimen (3): [[drug name]] 500 mg PO q12h for 14 (14–21) days
| |
| ***** Alternative regimen (1): [[drug name]] 500 mg PO q6h for 7–10 days
| |
| ***** Alternative regimen (2): [[drug name]] 500 mg PO q12h for 14–21 days
| |
| ***** Alternative regimen (3):[[drug name]] 500 mg PO q6h for 14–21 days
| |
| *** 2.2.2 '''Pediatric'''
| |
| **** Parenteral regimen
| |
| ***** Preferred regimen (1): [[drug name]] 50–75 mg/kg IV q24h for 14 (14–21) days (maximum, 2 g)
| |
| ***** Alternative regimen (1): [[drug name]] 150–200 mg/kg/day IV q6–8h for 14 (14–21) days (maximum, 6 g per day)
| |
| ***** Alternative regimen (2): [[drug name]] 200,000–400,000 U/kg/day IV q4h for 14 (14–21) days (maximum, 18–24 million U per day)
| |
| **** Oral regimen
| |
| ***** Preferred regimen (1): [[drug name]] 50 mg/kg/day PO q8h for 14 (14–21) days (maximum, 500 mg per dose)
| |
| ***** Preferred regimen (2): [[drug name]] 4 mg/kg/day PO q12h for 14 (14–21) days (maximum, 100 mg per dose)
| |
| ***** Preferred regimen (3): [[drug name]] 30 mg/kg/day PO q12h for 14 (14–21) days (maximum, 500 mg per dose)
| |
| ***** Alternative regimen (1): [[drug name]] 10 mg/kg PO q6h 7–10 days (maximum, 500 mg per day)
| |
| ***** Alternative regimen (2): [[drug name]] 7.5 mg/kg PO q12h for 14–21 days (maximum, 500 mg per dose)
| |
| ***** Alternative regimen (3): [[drug name]] 12.5 mg/kg PO q6h for 14–21 days (maximum,500 mg per dose)
| |
|
| |
|
| ==References== | | ==References== |